Elicio Therapeutics has priced a $15 million registered direct offering of common stock to support the Phase 1 clinical development of its lead immunotherapy candidate, ELI-002 7P, targeting KRAS-driven metastatic pancreatic cancer. The offering involves 4.38 million shares and is expected to close around July 6, 2026. Proceeds will also fund other pipeline programs and general corporate purposes. Elicio aims to advance its off-the-shelf immunotherapies, which could provide cost-effective and rapid treatment options for cancers driven by KRAS mutations, affecting about 25% of solid tumors.
Mohawk Industries will release its Q2 2026 financial results on July 30, followed by a live earnings call on July 31 at 11:00 a.m. ET. Investors can join via the company website or phone. Additionally, Mohawk announced a CEO succession plan: Paul De ...
K Wave Media has sold its entire Bitcoin holdings, totaling 88 BTC, to repay $6 million in debt. This marks a reversal from its previous plan to rapidly expand Bitcoin reserves to 10,000 BTC. The company is now shifting its strategic focus from Bitco...
Molecular Partners and Orano Med have dosed the first patients in a US Phase 1/2a trial of MP0712, a novel Radio-DARPin drug targeting DLL3, a protein highly expressed in small cell lung cancer and other neuroendocrine tumors. This therapy uses lead-...
Tether froze all USDT funds in 131 TRON wallets linked to the terrorist group ISIS-K following US Treasury sanctions. These wallets held over $1.4 million since 2023, with some funds routed to Syrian exchanges. This move blocks access to those funds,...
Oil prices remain stable with WTI holding at $67.81 and Brent at $73.06 as OPEC+ maintains production discipline while US shale supply continues to rise. Strong refinery activity supports demand for fuels and petrochemicals during the summer driving ...
